OriCell's GPC3 CAR-T therapy Ori-C101 receives NMPA clearance for Phase II liver cancer trial
June 08, 2026 | 10:00
OriCell Therapeutics has announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration to proceed to a confirmatory Phase II trial in late-line advanced hepatocellular carcinoma.
Latest News
Mobile Version